The commercialization of ingenol mebutate (Picato, LEO Pharma) a medication that is currently approved in the United States and many other countries for the treatment of actinic keratosis, is an example of how enthusiasm and commitment can drive innovation, a LEO Pharma general manager says.
Actinic Keratoses Evaluation
At the MauiDerm 2014 meeting, conference organizer George Martin, M.D., shared five clinical pearls for treating facial actinic keratosis (AK).
A new study suggests that topical 5-fluorouracil (5-FU) may increase the risk of morpheaform basal cell carcinoma (mBCC) in patients with previous skin cancers.
Dermatologists are using an evolving collection of combination therapies designed to address different aspects of disease, monotherapy limitations and failures, as well as enhance treatment.
New topical agents such as ingenol mebutate (Picato, Leo Pharma), reformulations of standing local treatments as well as combination therapies are not only proving to be very useful in the clearance of actinic keratosis (AK), but they also help address the common issues regarding field therapy.
A fractional resurfacing technique that uses a 1927 nm nonablative thulium laser reduces the number of facial actinic keratosis and provides noticeable clearance of photodamage, results of a recent study indicate.
Despite the number of currently available options for the treatment of actinic keratoses (AKs), dermatologists are still challenged by the occasional patient with widespread lesions refractory to multiple modalities.